medigraphic.com
ISSN 0185-6014 (Impreso)
Órgano oficial de difusión de la Federación Mexicana de Patología Clínica, AC y de la Asociación Latinoamericana de Patología Clínica/Medicina de Laboratorio

2000, Número 3

<< Anterior Siguiente >>

Rev Mex Patol Clin Med Lab 2000; 47 (3)


Biología molecular aplicada a la cirugía cardiaca

Riera KC, Argüero SR

Idioma: Español
Referencias bibliográficas: 31
Paginas: 150-155
Archivo PDF: 91.74 Kb.


RESUMEN

La cirugía cardiaca plantea la alternativa terapéutica actualmente más efectiva para la resolución de numerosas cardiopatías; dicha circunstancia ocupa a los investigadores debido a que estas últimas constituyen las principales causas de mortalidad en el ámbito mundial. La aplicación de la biología molecular en la cirugía cardiaca hace posible una atmósfera de expectativas muy interesantes para la medicina y la cardiología contemporáneas, que se observa en el terreno de los trasplantes cardiacos, la aterosclerosis, y la angiogénesis. El presente trabajo constituye un sumario de las principales líneas de investigación actual sobre la aplicación de la biología molecular en la cirugía cardiaca; estas consideraciones podrían modificar la calidad de vida de los pacientes, de manera que su análisis racional es indispensable.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Entwistle J, Wechsler A. Role of Gene Therapy in Cardiac Surgery. In:Franco K, Verrier. Advanced Therapy in Cardiac Surgery. B.C Decker Inc. Hamilton. Ontario, Canadá. 1999. p. 527-532.

  2. Cox T, Sinclair J. Biología Molecular en Medicina. En: Biología Molecular y el futuro de la Medicina. Editorial Médica Panamericana. Madrid, España: 1998: 334-345.

  3. Akoi M, Morishita R, Muraishi A, et al. Efficient in vivo gene transfer into Heart in the rat myocardium infarction model using the HVJ (hemagglutinating virus of Japan): liposome method. J Moll Cell Cardiol 1997; 29: 949-959.

  4. Donahue JK, Kikkawa K , Johns DC. Ultrarapid, highly efficient viral gene transfer to the Heart. Proc Natl Acad Sci USA 1997; 94: 4664-4668

  5. Wang J, Ma Y, Knechtle SJ. Adenovirus-mediated gene transfer into rat cardiac allografts. Transplantation 1996; 61: 1726-1729.

  6. Kohout TA, O Brian JJ, Gaa ST, et al. Novel adenovirus component system that transfects cultured cardiac cells with high efficiency. Circ Res 1996; 1996; 78: 971-977.

  7. Qin L, Ding Y, Bromberg JS. Gene transfer of transforming growth factor (1 prolong murine cardiac allograft survival inhibiting cell-mediated immunity. Hum Gene Ther 1996; 7: 1981-1988 (abstract).

  8. Brauner R, Wu L, Laks H et al. Intracoronary gene transfer of immunosuppressive cytokines to cardiac allografts: method and efficacy of adenovirus-mediated transduction. J Thorac Cardiovascular Surg 1997; 113: 1059-1066.

  9. Dalesandro J, Akimoto H , Gorman CM et al. Gene therapy for donor hearts. Ex vivo liposome – mediated transfection. J Thorac Cardiovasc Surg 1996; 111: 416-422.

  10. Schmoeckel M, Wallwork J, White D. Cardiac Xenograft Organs from transgenic pigs. En : Franco K, Verrier E. Advanced Therapy in Cardiac Surgery B.C Decker Inc. Hamilton. Ontario, Canadá. 1999. p . 520-526.

  11. Sharma A, Okabe J, Birch P et al. Reduction in the level of gal (a1,3) gal in transgenic mice and pigs by the expression of an a(1,2) fucosyltransferase. Proc Natl Acad Sci USA 1996; 93: 7190-7195.

  12. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of component- mediated endothelial cell cytotoxicity by decay- accelerating factor. Transplantation 1991; 52: 530-533.

  13. Bellgrau D, Gold D, Selawry H. A role for CD95 ligands in preventing graft rejection. Nature 1995; 377: 630-632.

  14. Guinan EC, Gribben JG, Bouswsitis VA et al. Pivotal role of the B7: CD28 pathway in transplantation tolerance and tumor immunity. Blood 1994; 84: 3261-3282.

  15. Patience C, Takeuchi Y, Weiss RA. Infection of human cells by endogenous retrovirus of pigs. Nat Med 1997; 3: 282-286 (abstract).

  16. Milano CA, Allen LF, Rockman HA et al. Enhanced myocardial function in transgenic mice overexpressing the beta-2 adrenergic receptor. Science 1994; 264: 582-586.

  17. Luo W, Grupp IL, Harrer J et al. Targeted abaltation of the phospholamban gen is associated with markedly enhanced myocardial contractility and loss of b-agonist stimulation. Circ Res 1994; 75: 401-409.

  18. Loer J, Patterson M, Quinones MJ, et al. Transplantation of fetal myocardial tissue into the infarcted myocardium of rat: potential method for repair of infarcted myocardium?. Circulation 1996; 94(Suppl Iia): 332-336.

  19. Murry CE, Kay MA, Barrosek T, et al. Muscle differentation during repair of myocardial necrosis in rats via gene transfer with MyoD. J Clin Invest 1996; 98: 2209-2217.

  20. Tam SKC, Gu W, Nadal- Ginard B, Vlahakes GJ. Molecular cardiomyoplasty: potential cardiac gene therapy for chronic heart failure. J Thorac Cardiovasc Surg 1995; 109: 918-924.

  21. Forough R, Koyama N, Hasenstab D et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell function in vitro and in vivo. Circ Res. 1996; 79: 812-820.

  22. Hanna AK, Fox JC , Neschis DG, et al. Antisense basic fibroblast growth factor gene transfer reduces neointimal thickening after arterial injury. J Vasc Surg 1997; 25: 320-325.

  23. von der Leyen HE, Gibbons GH, Morishita R et al. Gene therapy inhibiting neointimal vascular lesion-in vivo transfer of endothelial- cell nitric-oxide syntheses gene. Proc Natl Acad Sci USA 1995; 92: 1137-1141.

  24. Chang MW, Barr E, Seltzer J et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of retinoblastoma gene product. Science 1995; 267: 518-522.

  25. Mulhauser J, Merrill MJ, Pili R et al. VEGF 165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo. Circ Res 1995; 77: 1077-1086.

  26. Uchida Y, Yanagisawa-Miwa A, Nakamura F, Yamada K, Tomaru T, Kimura, Morita T. Angiogenic therapy of acute myocardial infarctation by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J 1995; 130; 6: 1182.

  27. Landau C, Jacobs AK, Haudenschild CC. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am Heart J 1995; 129; 5: 924-931.

  28. Lazarous D, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S, Robinson G, Stiber J, Correa R, Epstein S, Unger E. Circulation 1995; 91: 145-153.

  29. Harada K, Grossman W, Friedman M, Edelman ER, Prasad PV, Keighley CS, Manning WJ, Sellke FW, Simons M. Basic Fibroblast growth facor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994; 94; 2: 623-630.

  30. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Segni E, Varda-Bloom N, Nass D, Savion N. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993; 22: 2001-2006.

  31. Giordano FJ, Ping P, McKirnan, Nozaki S, DeMaria AN, Dillmann WH, Mathieu-Costello O, Hammond HK. Nat Med 1996; 5: 534-539.




2020     |     www.medigraphic.com